IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
University of Bologna, Bologna, Italy,
Oncol Res Treat. 2020;43(6):314-322. doi: 10.1159/000507334. Epub 2020 May 25.
Myxofibrosarcoma (MFS) is among the most highly complex sarcoma types. Molecular cytogenetic studies have identified a high level of genomic complexity.
This review provides an update of the current research related to MFS, with particular emphasis on emerging mechanisms of tumorigenesis and their potential therapeutic impact. Many novel possible molecular markers have been identified, not only for prognostication in MFS, but also to serve as possible therapeutic targets, and thereby improve clinical outcomes. However, the molecular pathogenesis of MFS remains incompletely understood. Key Messages: Patients suffering from advanced MFS might benefit from expanded molecular evaluation in order to detect specific expression profiles and identify drug-able targets. Moreover, immunotherapy represents an intriguingly perspective due to the presence of "T-cell inflamed" tumor microenvironment.
黏液纤维肉瘤(MFS)是最复杂的肉瘤类型之一。分子细胞遗传学研究已经确定了高水平的基因组复杂性。
本综述提供了 MFS 相关的最新研究进展,特别强调了肿瘤发生的新兴机制及其潜在的治疗影响。已经确定了许多新的可能的分子标志物,不仅可以用于 MFS 的预后,还可以作为可能的治疗靶点,从而改善临床结果。然而,MFS 的分子发病机制仍不完全清楚。
患有晚期 MFS 的患者可能受益于扩展的分子评估,以检测特定的表达谱并确定可治疗的靶点。此外,免疫疗法由于存在“T 细胞浸润”的肿瘤微环境,代表了一个有趣的前景。